The safety and efficacy of intrathecal adenosine in patients with chronic neuropathic pain
The safety and efficacy of intrathecal adenosine in patients with chronic neuropathic pain
复制标题
DOI：
10.1097/00000539-199907000-00023
复制
发表时间：
1999-07-01
影响因子：
5.7
通讯作者：
Sollevi, A
中科院分区：
文献类型：
--
作者：
Belfrage, M;Segerdahl, M;Sollevi, A
腺苷和腺苷类似物通过腺苷受体在脊髓和/或脊髓上水平的激活降低急性伤害性疼痛和神经性疼痛的动物模型中的疼痛样行为。这项开放性研究是一系列鞘内（IT）腺苷给药研究的第一个，用于评价14例患者的疗效和副作用。所有患者均患有慢性神经性疼痛，主要是创伤性疼痛，伴有触觉痛觉过敏和/或异常性疼痛。评价了IT腺苷（500 μ g [n = 9]或1000 μ g [n = 5]）的作用。绘制了触觉疼痛的近似区域。在注射前和注射后60分钟评估自发性和诱发性疼痛（视觉模拟量表评分0-100）和触觉疼痛阈值。注射引起短暂的疼痛（
Adenosine and adenosine analogs decrease pain-like behavior in animal models of both acute nociceptive and neuropathic pain via adenosine receptor activation at spinal and/or supraspinal levels. This open study is the first in a series of intrathecal (IT) adenosine administration studied for the evaluation of efficacy and side effects in 14 patients All had chronic neuropathic pain with tactile hyperalgesia and/or allodynia primarily of traumatic origin. The effects of IT adenosine (500 mu g [n = 9] or 1000 mu g [n = 5]) were evaluated. Approximate areas of tactile pain were mapped. Spontaneous and evoked pain (visual analog scale score 0-100) and tactile pain thresholds were assessed before and 60 min after injection. The injection caused transient pain (